Whittier Trust Co. Cuts Stock Holdings in Solventum Co. (NYSE:SOLV)

Whittier Trust Co. decreased its position in shares of Solventum Co. (NYSE:SOLV) by 14.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,965 shares of the company’s stock after selling 854 shares during the period. Whittier Trust Co.’s holdings in Solventum were worth $328,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Modus Advisors LLC purchased a new stake in shares of Solventum during the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC purchased a new stake in shares of Solventum during the fourth quarter valued at approximately $26,000. Crews Bank & Trust purchased a new stake in shares of Solventum during the fourth quarter valued at approximately $32,000. True Wealth Design LLC lifted its position in Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after purchasing an additional 471 shares during the period. Finally, Synergy Asset Management LLC bought a new position in Solventum during the fourth quarter valued at approximately $35,000.

Solventum Price Performance

SOLV stock opened at $74.00 on Monday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a 50-day moving average price of $75.17 and a 200 day moving average price of $71.61. The stock has a market cap of $12.80 billion and a PE ratio of 26.91.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group increased their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday, March 3rd. Mizuho raised their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Piper Sandler raised their target price on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Finally, Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.